Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 2 (2005), Issue 8 (August)

1. Dipeptidyl peptidase IV in tumor progression.
   Biochim Biophys Acta, 1751(1): 45-51. [Abstract] [Full-text]
2. Granulosa theca cell tumor with luteoma in the ovary of a bonnet monkey (Macaca radiata).
   J Med Primatol, 34(4): 219-23. [Abstract] [Full-text]
3. Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation.
   Exp Cell Res, 308(2): 241-53. [Abstract] [Full-text]
4. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer.
   Cancer Res, 65(15): 7000-6. [Abstract] [Full-text]
5. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
   Cancer Res, 65(15): 6910-8. [Abstract] [Full-text]
6. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.
   Cancer Res, 65(15): 6789-800. [Abstract] [Full-text]
7. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells.
   Cancer Res, 65(15): 6701-10. [Abstract] [Full-text]
8. Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators.
   Cancer Res, 65(15): 6593-600. [Abstract] [Full-text]
9. A transforming growth factor-beta receptor-interacting protein frequently mutated in human ovarian cancer.
   Cancer Res, 65(15): 6526-33. [Abstract] [Full-text]
10. Oncogenic transformation by SEI-1 is associated with chromosomal instability.
    Cancer Res, 65(15): 6504-8. [Abstract] [Full-text]
11. Interferon-alpha gene therapy by lentiviral vectors contrasts ovarian cancer growth through angiogenesis inhibition.
    Hum Gene Ther, 16(8): 957-70. [Abstract] [Full-text]
12. Suppression of the TIG3 tumor suppressor gene in human ovarian carcinomas is mediated via mitogen-activated kinase-dependent and -independent mechanisms.
    Int J Cancer, 116(6): 894-902. [Abstract] [Full-text]
13. The human ovarian teratocarcinoma cell line PA-1 demonstrates a single translocation: analysis with fluorescence in situ hybridization, spectral karyotyping, and bacterial artificial chromosome microarray.
    Cancer Genet Cytogenet, 161(1): 63-9. [Abstract] [Full-text]
14. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use.
    Breast, 14(4): 264-8. [Abstract] [Full-text]
15. Is loss of heterozygosity at 9q22.3 (PTCH gene) and 19p13.3 (STK11 gene) involved in the pathogenesis of ovarian stromal tumors?
    Hum Pathol, 36(7): 792-6. [Abstract] [Full-text]
16. Aromatase and comparative response to its inhibitors in two types of endometrial cancer.
    J Steroid Biochem Mol Biol, 95(1): 71-4. [Abstract] [Full-text]
17. Lactase persistence and ovarian carcinoma risk in Finland, Poland and Sweden.
    Int J Cancer, 117(1): 90-4. [Abstract] [Full-text]
18. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study.
    Oncology, 68(2): 154-61. [Abstract] [Full-text]
19. Sites of bowel resected to achieve optimal ovarian cancer cytoreduction: implications regarding surgical management.
    Am J Obstet Gynecol, 193(2): 582-6; discussion 586-8. [Abstract] [Full-text]
20. Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer.
    Am J Obstet Gynecol, 193(2): 568-74; discussion 574-6. [Abstract] [Full-text]
21. 'Indirect' BRCA1/2 testing: a useful approach in hereditary breast and ovarian cancer families without a living affected relative.
    Clin Genet, 68(3): 228-33. [Abstract] [Full-text]
22. Psychological functioning in African American women at an increased risk of hereditary breast and ovarian cancer.
    Clin Genet, 68(3): 222-7. [Abstract] [Full-text]
23. Ovarian cancer is a heterogeneous disease.
    Cancer Genet Cytogenet, 161(2): 170-3. [Abstract] [Full-text]
24. THY-1 induction is associated with up-regulation of fibronectin and thrombospondin-1 in human ovarian cancer.
    Cancer Genet Cytogenet, 161(2): 151-8. [Abstract] [Full-text]
25. Identification and characterization of membralin, a novel tumor-associated gene, in ovarian carcinoma.
    Biochim Biophys Acta, 1730(2): 96-102. [Abstract] [Full-text]
26. Current concepts of treatment strategies in advanced or recurrent ovarian cancer.
    Oncology, 68(4): 293-8. [Abstract] [Full-text]
27. Anti-tumor antibodies in ovarian cancer.
    Am J Reprod Immunol, 54(2): 55-62. [Abstract] [Full-text]
28. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study.
    J Clin Oncol, 23(24): 5605-12. [Abstract] [Full-text]
29. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer.
    J Clin Oncol, 23(24): 5597-604. [Abstract] [Full-text]
30. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system.
    J Clin Oncol, 23(24): 5588-96. [Abstract] [Full-text]
31. Hereditary ovarian cancer.
    Hum Pathol, 36(8): 861-70. [Abstract] [Full-text]
32. Serous borderline tumours of the ovary.
    Histopathology, 47(3): 310-5. [Abstract] [Full-text]
33. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features.
    Histopathology, 47(3): 231-47. [Abstract] [Full-text]
34. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma.
    Cancer, 104(5): 1004-12. [Abstract] [Full-text]
35. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.
    Eur J Surg Oncol, 31(7): 792-7. [Abstract] [Full-text]
36. Physical activity and the risk of ovarian cancer: a case-control study in Canada.
    Int J Cancer, 117(2): 300-7. [Abstract] [Full-text]
37. Functional and molecular mapping of uncoupling between vascular permeability and loss of vascular maturation in ovarian carcinoma xenografts: the role of stroma cells in tumor angiogenesis.
    Int J Cancer, 117(2): 202-11. [Abstract] [Full-text]
38. Substantial proportions of identical beta-chain T-cell receptor transcripts are present in epithelial ovarian carcinoma tumors.
    Cell Immunol, 234(2): 81-101. [Abstract] [Full-text]
39. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer.
    Proc Natl Acad Sci U S A, 102(35): 12519-24. [Abstract] [Full-text]

© 2004-2012 Ovarian Cancer Research Today. All Rights Reserved.